Genomic Profiling and Matched Therapy for Recurrent or Metastatic Salivary Gland Neoplasms
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 114
- 试验地点
- 1
- 主要终点
- Number of participants with complete and partial response to unmatched therapy Selinexor compared to matched therapies
研究概览
简要总结
This is a study of select drug therapies in patients with salivary gland cancer. The study has two phases: a molecular profiling phase (phase 1) and a treatment phase (phase 2).
Based on the Molecular profiling results in phase the participants will receive matched treatment if a specific aberration is identified or will receive treatment with Selinexor if unmatched and no druggable aberration is identified.
详细描述
In molecular profiling phase of the study, participants will provide a sample of their tumor tissue to test for changes in certain genes that show whether certain drug treatments will be more useful than others.
Once participants have undergone molecular profiling, they will be offered a drug treatment depending on the results. Certain drug treatments are designed to target certain gene changes. If there is a matching drug treatment, participants will be offered that treatment (either outside a clinical trial or within a clinical trial). If there are no gene changes or there are changes to genes were there are no drug treatments available for those certain changes, participants will be offered the study drug, Selinexor.
Cancer is the uncontrolled growth of cells. Research shows that one way cancer cells can grow uncontrollably is when certain proteins, called exporter proteins, are present in high levels in the body. These proteins prevent certain other proteins important in protecting cells from becoming cancerous and important in the controlling the growth of cells, from working. The study drug Selinexor is new class of drug called Selective Inhibitor of Nuclear Export (SINE) that blocks the exporter proteins from working which may allow the other proteins to work and slow or stop tumors from growing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(Phase 1, Molecular Profiling):
- •Have available archival tumor tissue or fresh tumor specimen from diagnostic histological tissue for molecular profiling.
- •Histological or cytological proof of malignant salivary gland tumor
- •ECOG performance score 0-2
- •Documented evidence of recurrent or metastatic disease
- •Inclusion Criteria (Phase 2, Treatment):
- •Interpretable result of molecular profiling in the molecular profiling phase of this study
- •Advanced recurrent or metastatic salivary gland cancer for which no curative therapy exists
- •Evidence of clinical or radiological disease progression at the time of study treatment
- •At least one measurable target lesion as defined by RECIST 1.1
- •Must have adequate hematological, liver, renal and cardiac function
- •No concomitant use of drugs which may prolong QTc interval
- •No history of serious cardiac illness
- •No serious medical conditions that might be aggravated by treatment or limit compliance.
- •Central nervous system metastases are permitted provided these are clinically stable
- •Able to take oral medication and have no evidence of bowel obstruction, infectious/inflammatory bowel disease
- •No other active malignancy at any other site
- •18 years of age or older
- •Measureable disease as defined by RECIST v1.1
- •Not receiving any other concurrent investigational agent
- •If the matched treatment is in the context of another phase I trial, the eligibility criteria of the enrolled trial will be used instead of the criteria from this trial
排除标准
- •(Phase 1, Molecular Profiling):
- •Refuses to have tumor tissue undergo molecular profiling
- •Not enough tumor tissue for molecular profiling
- •Life expectancy less than 3 months
- •Exclusion Criteria (Phase 2, Treatment):
- •Had stopped the previous treatment but showed no clinical or radiological evidence of disease progression
- •Have received the same drug treatment of assignment to the specific arm before the enrolment in to treatment phase (phase 2)
研究组 & 干预措施
Unmatched Treatment (Selinexor)
Selinexor, 30mg/m2, by mouth, twice weekly, every 28 day cycles.
If patients have a "druggable" aberration but there is no access to the relevant agent, then patients will receive selinexor
干预措施: Selinexor (Drug)
Matched Therapy
EGFR or HER2 Inhibitor,FGFR Inhibitor,C-KIT Inhibitor, Anti-androgen ,NOTCH Inhibitor,MEK or PI3K Inhibitor .
If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator.
干预措施: EGFR or HER2 Inhibitor (Drug)
Matched Therapy
EGFR or HER2 Inhibitor,FGFR Inhibitor,C-KIT Inhibitor, Anti-androgen ,NOTCH Inhibitor,MEK or PI3K Inhibitor .
If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator.
干预措施: FGFR Inhibitor (Drug)
Matched Therapy
EGFR or HER2 Inhibitor,FGFR Inhibitor,C-KIT Inhibitor, Anti-androgen ,NOTCH Inhibitor,MEK or PI3K Inhibitor .
If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator.
干预措施: C-KIT Inhibitor (Drug)
Matched Therapy
EGFR or HER2 Inhibitor,FGFR Inhibitor,C-KIT Inhibitor, Anti-androgen ,NOTCH Inhibitor,MEK or PI3K Inhibitor .
If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator.
干预措施: Anti-androgen (Drug)
Matched Therapy
EGFR or HER2 Inhibitor,FGFR Inhibitor,C-KIT Inhibitor, Anti-androgen ,NOTCH Inhibitor,MEK or PI3K Inhibitor .
If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator.
干预措施: NOTCH Inhibitor (Drug)
Matched Therapy
EGFR or HER2 Inhibitor,FGFR Inhibitor,C-KIT Inhibitor, Anti-androgen ,NOTCH Inhibitor,MEK or PI3K Inhibitor .
If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator.
干预措施: MEK or PI3K Inhibitor (Drug)
结局指标
主要结局
Number of participants with complete and partial response to unmatched therapy Selinexor compared to matched therapies
时间窗: 4 years
Overall Response rate in the setting of matched and unmatched therapy.
次要结局
- Number of participants with complete, partial and/or stable disease to unmatched therapy Selinexor compared to matched therapies(4 years)
- Length of time that participant's disease does not worsen(6 months)
- Percentage of each molecular aberrations in metastatic salivary gland tumors(4 years)